A new gene regulatory program was revealed by Logotheti et al.,48 in which E2F1‐inducible SLC16A1‐AS1 forms a complex with its transcription factors to promote cancer metabolic reprogramming to obtain a mixed oxidative profile that favors bladder cancer (BC) aggressiveness. The gene discussed is E2F1; the disease is breast cancer.